Last reviewed · How we verify
FXI-GalNAc-siRNA
FXI-GalNAc-siRNA is a novel RNA interference therapeutic being developed by Sirnaomics for the treatment of thrombotic disorders. Currently in Phase 1 trials, it targets Factor XI to reduce the risk of thrombosis without increasing bleeding risk.
At a glance
| Generic name | FXI-GalNAc-siRNA |
|---|---|
| Also known as | FXI-GalNAc-siRNA Solution for Injection |
| Sponsor | Sirnaomics |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FXI-GalNAc-siRNA CI brief — competitive landscape report
- FXI-GalNAc-siRNA updates RSS · CI watch RSS
- Sirnaomics portfolio CI